# Targeting Pancreatic Cancer Senescence with ImmunoPET > **NIH NIH K99** · SLOAN-KETTERING INST CAN RESEARCH · 2024 · $148,282 ## Abstract Project Summary Pancreatic cancer is the fourth-most lethal cancer across both sexes, with five-year overall survival of all stages at 12%. In patients diagnosed with pancreatic cancer, first-line chemotherapy with gemcitabine and nab- paclitaxel with or without FOLFIRINOX often requires second-line chemotherapy combinations, with median survival ranging from 6 to 26 months. New therapeutic combinations are needed. One promising approach for overcoming this impasse centers on senescence. Cells can undergo senescence in response to replication, oncogene induction, or targeted drug therapy, including most chemotherapeutic regimens used for pancreatic cancer. However, while senescent cells have been implicated in tumorigenesis via pro-inflammatory factors seen in circulation as part of the senescence-associated secretory phenotype (SASP), their direct tumoral activity over time and distribution elsewhere is unknown. Moreover, current senescence imaging agents are small molecules measuring lysosome activity. An antibody-based approach, in contrast, offers greater targeting specificity and biological links to surface antigens. Noninvasive PET tools for senescence antigens will improve our ability to identify senescence with the option to change the isotope for targeted alpha therapy in the tumor. The members of the Scott Lowe Lab have pioneered senescence induction in pancreatic cancer with the combination of trametinib (T) and palbociclib (P), leading to the release of cytokines as SASP remodels the tumor microenvironment and beyond. Using immunoPET to study combination TP therapy in their models, we have found that shed antigens such as VEGF and IL-6 are decreased in the tumor environment while membrane- bound antigens like uPAR are elevated. We hypothesize that senescence induced by chemotherapy is temporal and immunoPET can be used noninvasively to quantify these dynamics during therapy. In collaboration with the Scott Lowe and Christine Iacobuzio-Donahue Labs at Memorial Sloan Kettering Cancer Center, we will use noninvasive immunoPET imaging to (1) quantify previously identified senescence markers during senescence- inducing therapy in human and murine pancreatic cancer models, (2) independently discover more senescence- specific markers, and (3) use targeted immunoPET agents for endoradiotherapy and improved senolytic delivery. In collaboration with Patricia Ribeiro Pereira at Washington University at St. Louis, we will also identify pharmacologic methods to prevent antigen shed, while advanced PET reconstruction with Joaquin Lopez- Herraiz at Complutense University Madrid will enable dual radiotracer immunoPET imaging of immune populations during therapy. Our efforts to quantify senescence in vivo with the proposed markers and enhance targeted alpha therapy with senescence will be guided by Dr. Lisa Bodei for clinical relevance and Andrea Schietinger for immunological insight. This work will unlock multiple directions in the precision theranos... ## Key facts - **NIH application ID:** 10887059 - **Project number:** 1K99CA276804-01A1 - **Recipient organization:** SLOAN-KETTERING INST CAN RESEARCH - **Principal Investigator:** Edwin Charles Pratt - **Activity code:** K99 (R01, R21, SBIR, etc.) - **Funding institute:** NIH - **Fiscal year:** 2024 - **Award amount:** $148,282 - **Award type:** 1 - **Project period:** 2024-05-01 → 2026-04-30 ## Primary source NIH RePORTER: https://reporter.nih.gov/project-details/10887059 ## Citation > US National Institutes of Health, RePORTER application 10887059, Targeting Pancreatic Cancer Senescence with ImmunoPET (1K99CA276804-01A1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10887059. Licensed CC0. --- *[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*